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Abstract
Background: Nuclear import of the HIV-1 reverse transcription complex (RTC) is critical for
infection of non dividing cells, and importin 7 (imp7) has been implicated in this process. To further
characterize the function of imp7 in HIV-1 replication we generated cell lines stably depleted for
imp7 and used them in conjunction with infection, cellular fractionation and pull-down assays.
Results: Imp7 depletion impaired HIV-1 infection but did not significantly affect HIV-2, simian
immunodeficiency virus (SIVmac), or equine infectious anemia virus (EIAV). The lentiviral
dependence on imp7 closely correlated with binding of the respective integrase proteins to imp7.
HIV-1 RTC associated with nuclei of infected cells with remarkable speed and knock down of imp7
reduced HIV-1 DNA nuclear accumulation, delaying infection. Using an HIV-1 mutant deficient for
reverse transcription, we found that viral RNA accumulated within nuclei of infected cells,
indicating that reverse transcription is not absolutely required for nuclear import. Depletion of
imp7 impacted on HIV-1 DNA but not RNA nuclear import and also inhibited DNA transfection
efficiency.
Conclusion: Although imp7 may not be essential for HIV-1 infection, our results suggest that imp7
facilitates nuclear trafficking of DNA and that HIV-1 exploits imp7 to maximize nuclear import of
its DNA genome. Lentiviruses other than HIV-1 may have evolved to use alternative nuclear import
receptors to the same end.
Background
Akin to other lentiviruses, HIV-1 is able to infect primary
non-dividing cells, such as tissue macrophages, microglial
cells and CD4+ memory T-cells as well as cells artificially
arrested in the cell cycle (reviewed in reference [1]). These
primary cells represent key in vivo targets for virus trans-
mission and AIDS pathogenesis, hence the importance of
understanding how HIV-1 can traverse the intact nuclear
envelope.
Biochemical studies have shown that the ability of HIV-1
to infect non-dividing cells depends on the active nuclear
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import of its intracellular reverse transcription/pre-inte-
gration complex (RTC/PIC) [2], and both viral and cellu-
lar elements have been implicated in this process [1,3].
Chimeric viruses, in which HIV-1 Gag has been replaced
with Moloney murine leukaemia (MLV) Gag, infect cell
cycle-arrested cells with very low efficiency [4]. Within
MLV Gag, the CA protein appears to be the dominant neg-
ative regulator of nuclear import [4]. MLV can only infect
cycling cells [5-7], and its RTC retains a significant portion
of CA protein until after nuclear entry [8]. Moreover, HIV-
1 mutants that do not shed enough p24 CA are defective
in nuclear import and integration [9]. Based on this evi-
dence, it has been proposed that appropriate shedding of
CA protein from the RTC/PIC is a key step for nuclear
import of HIV-1 [1,10]. HIV-1 capsid exceeds the maximal
functional diameter of the nuclear pore complex, hence it
is likely that uncoating takes place before RTCs can be
imported into nuclei.
Additional viral elements implicated in HIV-1 nuclear
import include p17 MA, Vpr, integrase (IN), and the cen-
tral polypurine tract (cPPT) [1,3]. The cPPT is a second ori-
gin of DNA plus strand synthesis located within pol that,
after completion of reverse transcription, results in a short
(approximately 100 nt) stretch of triple stranded DNA
[11]. When included in HIV-1 vectors, the cPPT increases
nuclear accumulation of vector DNA 2- to 10-fold
(reviewed in reference [1]), although there is controversy
on the magnitude of its effect in the context of wild-type
virus replication [12-16]. Recent data suggest that forma-
tion of the triple stranded DNA stretch promotes nuclear
transport of HIV-1 PICs by inducing timely uncoating of
the viral capsid [17].
Following uncoating, the HIV-1 RTC, containing viral
nucleic acids as well as cellular and viral components,
must engage one or more cellular pathways for nuclear
import. Several cellular factors have been shown to partic-
ipate in the trafficking RTCs to the nucleus, including fas-
ciculation and elongation protein zeta-1 (FEZ1), Nup98,
Nup358, Nup153, importin 7 (imp7), and transportin 3/
transportin SR-2 (tnp3) [18-23]. Furthermore, recent evi-
dence indicated that HIV-1 can recruit a newly discovered
cellular pathway for retrograde transport of tRNAs in
mammalian cells to promote RTC nuclear import [24,25].
Imp7 is a nucleocytoplasmic transport protein closely
related to impβ and its N-terminus binds to RanGTP [26].
Imp7 serves as an import factor for some ribosomal pro-
teins, the glucocorticoid receptor, zinc finger protein EZI,
ERK MAP kinase, activated Smads, and, as a heterodimer
with impβ, histone H1 [27-32]. Moreover, nuclear import
of the adenoviral DNA-binding protein pVII and of HIV-1
integrase (IN) and Rev is supported by imp7 and other
importins, whereas adenovirus type 2 nuclear import
depends on the imp7/impβ heterodimer [20,33-35].
Using in vitro nuclear import assays, Imp7 was shown to
promote nuclear import of HIV-1 RTCs in a Ran- and
energy-dependent manner. Furthermore, transient knock
down of imp7 by siRNA inhibited HIV-1 infection [20],
although the latter observation has been questioned [36].
Double imp7 knock down in both viral producer cells and
target cells was required for maximal inhibition of viral
infection [37]. Imp7 was shown to bind to the C-terminal
region of HIV-1 IN, and mutant viruses unable to interact
with imp7 were defective in both reverse transcription and
nuclear entry [37].
To gain a better understanding of HIV-1 nuclear traffick-
ing, we established cells stably knocked down for imp7
and performed infection and biochemical fractionation
assays. Our results indicate that HIV-1, but not HIV-2, SIV-
mac or EIAV, recruits imp7 via interaction with IN to max-
imise viral DNA nuclear import. Our data argue that the
closely related lentiviruses may have evolved different and
probably redundant nuclear import mechanisms.
Results
To investigate the function of imp7 in HIV-1 infection,
HeLa polyclonal cell lines with a stable imp7 knock down
(KD) were generated by shRNA expressed from a lentiviral
vector [38]. Control cells were similarly generated that
harboured a shRNA targeting the Discosoma corallimor-
pharian DsRed mRNA (DxR). The control shRNA effec-
tively knocked down expression of the DxR protein in
control experiments, indicating that it was indeed
recruited into the RISC complex and was functional (not
shown). As an additional control for specificity, polyclo-
nal imp7 KD cells were back complemented with an imp7
cDNA harbouring two silent mutations making it resistant
to the imp7 shRNA. Cells were analyzed by Western blot-
ting with antibodies against imp7 and Ran (as a loading
control). Imp7 KD in HeLa cells was robust and specific
and back complementation with the mutant cDNA effec-
tively restored imp7 expression. Effective imp7 KD was
also achieved in human lymphocytic Jurkat cells (Figure
1A).
Imp7 KD cells grew slower than control DxR KD cells and
back complemented cells, consistent with our previous
findings using transient imp7 KD in human cells [20].
Importantly, however, cell viability was not significantly
affected by stable depletion of imp7 (Additional file 1 and
Table 1). Profiling of the cell cycle with propidium iodide
showed minor differences between imp7 KD and control
cells with a trend towards a reduction of the percentage of
cells in G1 and an increase in S (HeLa) and G2/M phases
(Jurkat) (Table 1). These results suggested that imp7 KD
modestly delayed cell cycle progression.
The imp7 KD cells were infected with different doses of
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Generation of stable imp7 knock down (KD) cells Figure 1
Generation of stable imp7 knock down (KD) cells. (A) Left panels: Western blot with an anti-imp7 antibody and an anti-
Ran antibody on total cell extracts obtained from a low passage polyclonal population of DxR KD (lane 1) and imp7 KD HeLa 
cells (lane 2), a polyclonal population of DxR KD (lane 3), imp7KD (lane 4) and the same imp7 KD population expressing an 
imp7 cDNA with two silent mutations making it resistant to the shRNA (imp7+7R) (lane 5). Note that cells in lanes 3 to 5 
were grown for 4 weeks to allow for selection of the imp7+7R line. Right panel: Western blot with an anti-imp7 antibody and 
an anti-Ran antibody on total cell extracts obtained from a polyclonal population of DxR KD cells (lane 1) and imp7 KD Jurkat 
cells (lane 2). (B) DxR KD (shDxR), imp7 KD (shimp7) and imp7 back complemented (shimp7+7R) HeLa cells were plated 
onto 24-well plates to have the same confluency by the next day and infected with five fold serial dilutions of a VSV-G pseudo-
typed HIV-1 vector (pHR') expressing GFP. Twenty-four hours after infection the percentage of GFP+ cells was measured by 
flow cytometry. (C) Cells were infected with three fold serial dilutions of a VSV-G pseudotyped SIVmac vector expressing GFP 
and analysed as in (B). Similar results were obtained in least three independent experiments using different virus stocks. (D) 
Western blot with an anti-imp7 antibody and an anti-Ran antibody on total cell extracts obtained from a polyclonal population 
of DxR KD HeLa cells (lane 1) and three different imp7 KD clones (lane 2, clone 2; lane 3, clone 4; lane 4, clone 8). The bands 
were scanned and the intensity of the imp7 band relative to Ran is shown below each sample. (E) DxR KD cells and imp7 KD 
clonal cell populations were infected with a VSV-G pseudotyped HIV-1 vector (pHR') or SIVmac vector expressing GFP at an 
MOI of 0.03 and the percentage of GFP+ cells counted 24 hours after infection by flow cytometry. Data are expressed as aver-
age percentage of infection relative the parent line control (shDxR) ± SD of three independent experiments. (F) DxR KD and 
imp7 KD Jurkat cells were infected with three fold serial dilutions of a VSV-G pseudotyped HIV-1 vector (pCSGW) expressing 
GFP and the percentage of GFP+ cells counted 24 hours after infection by flow cytometry. Similar results were obtained in two 
additional experiments using different virus stocks.Retrovirology 2009, 6:11 http://www.retrovirology.com/content/6/1/11
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HIV-1 vectors expressing green fluorescent protein (GFP)
[39]. The results in Figure 1B show that imp7 KD resulted
in a specific inhibition of HIV-1 vector infection. Similar
results were also obtained with a different HIV-1 derived
vector [40], as well as with a full length HIV-1LAIΔenv virus
that expressed GFP in place of Nef (not shown) [4].
Intriguingly, when challenged with a simian immunode-
ficiency virus (SIVmac) vector [41] imp7 and DxR KD cells
were equally infected (Figure 1C). HIV-2 infection was
very modestly impaired in imp7 KD cells (not shown).
These unexpected results indicated that cell toxicity or
other non-specific side effects could not explain the lower
levels of HIV-1 infection observed in imp7 KD cells. Sev-
eral imp7 KD HeLa clones were examined. Imp7 protein
levels in these clones ranged from approximately 15% to
6% of those in the parental cell line (Figure 1D), and a
correlation between reduction in HIV-1 infection and lev-
els of imp7 KD was apparent (Figure 1E). The efficiency of
HIV-1 vector infection was also lower in imp7 KD com-
pared to control DxR KD Jurkat cells (Figure 1F). Taken
together, these results indicated that HIV-1 infection was
specifically impaired in imp7 KD cells.
Inhibition of HIV-1 infection in imp7 KD cells was maxi-
mal between MOIs of 0.01 and 0.06 and was partially
overcome at an MOI ≈ 1 (Additional file 2). To examine if
imp7 in the producer cells was important, virus was pro-
duced in imp7 KD or DxR cells, normalized for RT activity
and used to infect imp7 KD or DxR target cells at an MOI
of 0.05. In agreement with a previous report [37], the virus
produced in imp7 KD cells had a lower relative infectivity
compared to virus produced in DxR cells. However the
difference in infectivity between the two viruses did not
reach statistical significance in imp7 KD target cells (Addi-
tional file 2).
Cell cycle arrest does not influence HIV-1 infection 
efficiency in imp7 KD cells
Imp7 may be required to promote RTC/PIC nuclear trans-
location only when the nuclear envelope is present. Hence
in the experiments shown in Figure 1, HIV-1 might have
accessed the nucleus in mitotic cells when the nuclear
envelope was dissolved, independently from imp7. To test
this possibility, cells were treated with aphidicolin to
block progression of the S-phase. Flow cytometry analysis
confirmed that exposure to the drug inhibited accumula-
tion of cells in the S-phase (Figure 2A). Cell-cycle arrest
increased susceptibility of the cells to infection with HIV-
1, HIV-2 and SIVmac (Figure 2B). Importantly, the relative
difference in HIV-1 infection efficiency between DxR and
imp7 KD cells observed in cycling cells was maintained
following cell cycle arrest (Figure 2B). In contrast, infectiv-
ity of SIVmac and HIV-2 were not affected in imp7 KD
cells in either condition (Figure 2B).
The binding affinity of different lentiviral INs for imp7 
correlates with infection phenotype in imp7 KD cells
The finding that SIVmac and HIV-2 infection was not
impaired in imp7 KD cells was unexpected and we sought
to understand the reason for this difference with HIV-1.
Imp7 was shown to bind HIV-1 IN [20,37], and the muta-
tions affecting this interaction resulted in viruses defective
for reverse transcription and nuclear import [37], support-
ing its functional relevance. Hence several lentiviral INs
were examined in pull down assays to test their ability to
interact with imp7. GST-imp7 was immobilized on glu-
tathione sepharose beads and the IN proteins from HIV-1,
HIV-2, SIVmac, EIAV, and bovine immunodeficiency
virus (BIV) were tested. GST-LEDGF326–530, containing the
IN binding domain (IBD) of LEDGF/p75 [42], the host
factor displaying broad affinity for INs of lentiviral origin
[43-46], and GST were used as positive and negative con-
trols, respectively. In agreement with previously reported
results [20,37] GST-Imp7 efficiently pulled down HIV-1
IN (Figure 3A). In contrast, although copious amounts of
all lentiviral INs were recovered with GST-LEDGF326–530,
the INs from HIV-2, SIVmac, and BIV only weakly inter-
acted with Imp7, and no detectable interaction was
observed for EIAV IN (Figure 3A). Importantly, none of
the IN proteins were recovered with GST- loaded resin,
confirming specificity of the observed interactions (Figure
3A). Essentially identical results were obtained in a reverse
pull down experiment using hexahistidine-tagged INs
immobilized on Ni-NTA agarose beads and untagged
Imp7 (Figure 3B). The interaction between nuclear import
receptors and their cargo are generally mediated by
charge-charge interactions [28]. Concordantly, the imp7-
IN interaction was sensitive to the ionic strength of the
pull down buffer (Figure 3C). However, while in the pres-
ence of 400 mM NaCl the interaction of imp7 with HIV-1
IN was still detectable, pull down of HIV-2 IN was abol-
ished (Figure 3C). Overall, the infection phenotype of dif-
ferent lentiviruses in imp7 KD cells correlated well with
the affinity of their respective INs for imp7 as detected in
the pull down experiments (Figures 2B and 3D). These
Table 1: Effects of imp7 KD on cell viability and cell cycle 
progression
Cell type % Live % Dead % G1 % S % G2/M
HeLa DxR 98.81 1.2 59.39 16.12 21.29
HeLa CL2 97.69 2.31 57.37 17.91 18.7
HeLa CL4 98.72 1.28 56.11 18.29 21.4
HeLa7+7R 99.4 0.6 59.86 16.2 19.07
Jurkat DxR 89.21 10.79 56.8 13.42 16.64
Jurkat sh7 86.71 13.29 50.44 12.92 20.17
Cells were analyzed by flow cytometry following differential 
fluorescent staining of live and dead cells and propidium iodide 
staining to examine cell cycle.Retrovirology 2009, 6:11 http://www.retrovirology.com/content/6/1/11
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The effect of imp7 KD on HIV-1 infection is independent of cell-cycle arrest Figure 2
The effect of imp7 KD on HIV-1 infection is independent of cell-cycle arrest. (A) HeLa cells analyzed by FACS after 
staining with propidium iodide. Top panel, dot plot of forward and side scatter; the gated population was used for cell cycle 
analysis, middle panel, no aphidicolin, bottom panel, cells treated with 1.5 micrograms/ml aphidicolin. M1, G1 phase; M2, S 
phase; M3, G2/M phase. (B) FACS analyses of HeLa DxR and imp7 KD cells infected at an MOI of 0.03 with a VSV-G pseudo-
typed HIV-1 vector (pCSGW), SIVmac vector and HIV-2 vector in the absence or presence (Aph) of aphidicolin. Cells were 
analyzed for GFP expression 20–24 hours post infection. Bars represent the mean value ± SD of three independent experi-
ments. Infection levels with an MLV vector were 10 fold lower in aphidicolin-treated cells compared to control cells (not 
shown).Retrovirology 2009, 6:11 http://www.retrovirology.com/content/6/1/11
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Lentiviral IN affinity for imp7 correlates with infection phenotype in imp7 KD cells Figure 3
Lentiviral IN affinity for imp7 correlates with infection phenotype in imp7 KD cells. (A) GST-imp7 (top left), GST 
(middle), or GST-LEDGF326–530 (bottom) immobilized on glutathione sepharose beads were incubated in the absence (lane 1), 
or presence (lanes 2–6) of untagged recombinant HIV-1, HIV-2, SIVmac, EIAV, or BIV IN in the pull-down buffer containing 130 
mM NaCl. Proteins bound to glutathione sepharose beads were resolved in an SDS PAGE gel and detected by staining with 
Coomassie Blue. Input quantities of each soluble protein used are shown to the right. Migration positions of GST-Imp7, INs, 
GST, and GST-LEDGF326–530, and the molecular weight markers are indicated. (B) Non-tagged Imp7 was incubated in the 
absence (lane 3) or presence (lanes 4–9) of C-terminally hexahistidine-tagged INs from HIV-1, HIV-2, SIVmac, EIAV, BIV and 
Ni-NTA agarose beads in a pull down buffer containing 150 mM NaCl. Proteins captured on the resin were separated in a tri-
cine SDS PAGE gel and detected with Coomassie Blue. Lanes 1 and 2 show 100% and 20% Imp7 input, respectively. (C) GST 
(lanes 3, 6, 9, 12, 15), GST-LEDGF326–530 (lanes 4, 7, 10, 13, 16), or GST-imp7 (lanes 5, 8, 11, 14, 17) were incubated without 
(lanes 3–5), or with non-tagged HIV-1 (lanes 6–8, 12–14) or HIV-2 (lanes 9–11, 15–16) INs. The pull-down buffer contained 
150 mM (lanes 3–11) or 400 mM (lanes 12–17) NaCl. Lanes 1 and 2 contained input quantities of HIV-1 and HIV-2 INs, respec-
tively. (D) DxR KD and imp7 KD cell populations were infected with VSV-G pseudotyped HIV-1, (pHR'), SIVmac, HIV-2 and 
EIAV vectors expressing GFP at an MOI of 0.03 and the percentage of GFP+ cells counted 24 hours after infection by flow 
cytometry. Data are expressed as average percentage of infection relative to control (shDxR) ± SD of two independent exper-
iments performed in duplicate.Retrovirology 2009, 6:11 http://www.retrovirology.com/content/6/1/11
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results strongly support the functional relevance of HIV-1
IN interaction with imp7 and explain why lentiviruses
other than HIV-1 are not impaired in imp7 KD cells.
Efficient accumulation of HIV-1 DNA in nuclear fractions 
of infected cells
To test if nuclear import was the actual step inhibited in
imp7 KD cells, untreated or cell cycle-arrested cells were
co-infected with MLV and HIV-1 vectors [47]. Twenty-four
hours post infection, cells were subjected to fractionation
to separate nuclei from cytoplasm [48] (see also Figure 6),
and the distribution of MLV and HIV-1 DNA examined
using Taqman real time PCR. No "cross amplification"
was observed in independent reactions. MLV DNA was
distributed rather evenly in the nuclear and cytoplasmic
fractions of normal cells and was less abundant in the
nuclear fraction of cell cycle-arrested cells (Figures 4A and
4C). In contrast, HIV-1 DNA was found predominantly in
the nuclear fractions of both untreated and cell cycle-
arrested cells (Figures 4B and 4D). In fact, cell cycle-
arrested cells contained more HIV-1 DNA associated with
the nuclei than control cells, in agreement with the higher
infectivity observed following cell cycle arrest (Figure 2B).
However, considerably lower levels of HIV-1 DNA were
found in the nuclear fraction of imp7 KD cells compared
to DxR cells (Figure 4), in agreement with the infection
levels (Figure 2B). Taken together these results suggested
that imp7 KD inhibited HIV-1 accumulation at or within
the nuclei.
Imp7 influences the degree of HIV-1 nuclear import
The data shown in Figure 4B indicated that trafficking of
HIV-1 to the nucleus is remarkably efficient. To test if
imp7 KD influenced this process, a time course experi-
ment was carried out. Imp7 KD and DxR cells were
infected with an HIV-1 vector expressing GFP and the per-
centage of GFP+ cells, the amount of total and 2LTR circu-
lar viral DNA were measured 24 h, 48 h and 72 h post
infection (we were unable to detect 2LTR circular viral
DNA earlier than 24 h post-infection). HIV-1 infection
efficiency was significantly lower in imp7 KD than in DxR
cells at 24 h (Student t-test p < 0.005, n = 3), but was sim-
ilar at 48 h and 72 h post-infection (Figure 5A). Viral DNA
synthesis was equal in the two cell types (Figure 5B). Total
viral DNA steadily decreased from 24 h to 72 h post-infec-
tion at the same rate in both cell types, presumably due to
degradation and dilution of un-integrated viral DNA.
2LTR circular viral DNA, a hallmark of nuclear entry, was
consistently higher in DxR than in imp7 KD cells, with the
widest gap at 48 h, the difference being statistically signif-
icant (Student t-test, p < 0.03, n = 3) (Figure 5C). These
data suggested that imp7 KD perturbs HIV-1 DNA nuclear
import.
Imp7 KD inhibits HIV-1 DNA but not RNA nuclear import
DNA can be imported into the nucleus of non-dividing
cells [49,50], and imp7 has been shown to promote DNA-
containing HIV-1 RTCs nuclear import in an in vitro assay
[20]. Hence we hypothesized that HIV-1 RTCs and per-
haps DNA, in general, may both exploit imp7 to promote
their nuclear entry. Reverse transcription of the HIV-1
genome into a DNA molecule would then be a require-
ment for nuclear import.
To test this hypothesis, we infected HeLa cells with equal
amounts (p24-normalised) of a wild type or reverse tran-
scriptase (RT)-deficient HIV-1 vector. The latter carries an
inactivating mutation within the highly conserved
YMD185D motif of the RT catalytic site and, hence, is una-
ble to reverse transcribe [51,52]. The mutant virus dis-
plays no assembly, release or post-entry defects [38]. Four
hours post infection nucleic acids isolated from cytoplas-
mic and nuclear fractions were divided into two aliquots:
one aliquot was treated with RNAseA and used for DNA
quantification; the other aliquot was first digested with
RNAse-free DNAse and then used for first strand cDNA
synthesis. To check the effectiveness of the fractionation
procedure, the distribution of the spliced cyclophilin A
mRNA was examined by RT-PCR. Because cyclophilin A
mRNA is abundant [53], it served as an excellent control
for possible contamination of the nuclear fractions with
cytoplasmic material and as a internal standard for the
quality/quantity of cDNA synthesis. Figure 6A shows that
cytoplasmic contamination of the nuclear fraction was
less than 1%. Results shown in Figure 6A also indicated
that anything detected in the nuclear fraction was most
likely inside the nuclei and not simply associated with the
external nuclear envelope. The external nuclear mem-
brane is a functional part of the rough endoplasmic retic-
ulum (ER) [54], hence its incomplete dissociation should
result in detection of ribosome-bound cyclophilin A
mRNA in the nuclear fraction.
The distribution of HIV-1 RNA and DNA was examined by
Taqman real time PCR using primers specific for the vec-
tor sequence. Intriguingly, viral RNA was readily detected
in the nuclei of acutely infected cells (Figure 6B). This was
not due to small amounts of synthesized DNA present in
the RTCs because viral RNA was found in the nuclei of
cells infected with the mutant vector unable to reverse
transcribe (Figure 6B). Therefore, viral DNA synthesis
does not appear to be absolutely required for nuclear
import of the HIV-1 RTC.
Next, we tested if imp7 KD influenced the distribution of
viral DNA and RNA in acutely infected cells. The same
fractionation procedure was used, except that imp7 KD
and DxR KD cells were contrasted and infection was car-Retrovirology 2009, 6:11 http://www.retrovirology.com/content/6/1/11
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Rapid and efficient nuclear accumulation of HIV-1 DNA Figure 4
Rapid and efficient nuclear accumulation of HIV-1 DNA. Cells were plated in 10 cm plates, co-infected with a HIV-1 
and a MLV vector at an MOI of approximately 0.1, incubated at 4°C for 2 hours and then at 37°C for an additional 24 hours. 
Cytoplasm and nuclei were fractionated and the distribution of MLV vector DNA (A) and HIV-1 vector DNA (B) was exam-
ined by Taqman PCR in the same HeLa DxR cells. DxR and imp7 KD cells were co-infected with a MLV and a HIV-1 vector 
after treatment with 1.5 micrograms/ml aphidicolin for 24 hours. The distribution of MLV vector DNA (C) and HIV-1 vector 
DNA (D) was examined by Taqman PCR. Bars represent the mean value of two independent experiments. To normalise 
across experiments, the total amount of viral DNA detected in the cytoplasm was given an arbitrary value of 100.Retrovirology 2009, 6:11 http://www.retrovirology.com/content/6/1/11
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ried on for six hours to allow more time for the build up
of possible differences. These experiments confirmed that
viral RNA could be detected within the nuclei shortly after
infection. However, viral DNA accumulated more effi-
ciently in the nuclei of DxR cells than in those of imp7 KD
cells, and conversely viral RNA accumulated less effi-
ciently in the nuclei of DxR KD cells than in those of imp7
KD cells (Figure 6C), suggesting that DNA and RNA
nuclear import may compete for access or passage
through nuclear pore complexes. Of note, in all experi-
ments omission of RT during first strand cDNA synthesis
resulted in undetectable signals (not shown). Taken
together, these results suggested that imp7 KD selectively
inhibited viral DNA nuclear import.
Imp7 KD reduces the efficiency of plasmid DNA 
transfection
Results shown in Figure 6 suggested that imp7 KD selec-
tively inhibited nuclear import of HIV-1 DNA. To test if
imp7 could promote nuclear trafficking of other forms of
DNA, the efficiency of plasmid DNA transfection in imp7
and DxR KD cells was examined. To mimic more closely
the situation with the RTC/PIC, the HIV-1 vector plasmid
DNA was linearized by restriction enzyme digestion. As
shown in Figure 7, the efficiency of DNA transfection
(measured as the percentage of GFP+ cells) was signifi-
cantly lower in imp7 KD cells than in DxR KD cells and
this phenotype was reversed upon imp7 back comple-
mentation. Similar results were obtained in two different
Imp7 KD impacts on the efficiency of HIV-1 nuclear import Figure 5
Imp7 KD impacts on the efficiency of HIV-1 nuclear import. DxR and imp7 KD HeLa cells were infected with an HIV-
1 vector (pCSGW) at an MOI of approximately 0.1 and analyzed at the indicated time points by (A) flow cytometry to measure 
GFP+ cells, (B) Taqman PCR to measure total viral DNA copy number, (C) Taqman PCR to measure 2LTR circular DNA copy 
number. Data are expressed as mean value ± SD of three independent experiments. Statistical significance was calculated by 
the Student t-test (n = 3), ** p < 0.005.Retrovirology 2009, 6:11 http://www.retrovirology.com/content/6/1/11
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Imp7 KD inhibits viral DNA but not viral RNA accumulation in the nuclei Figure 6
Imp7 KD inhibits viral DNA but not viral RNA accumulation in the nuclei. (A) HeLa cells were infected with a 
DNAse-treated and purified HIV-1 vector and incubated for 2 hours at 4°C and then 4–6 hours at 37°C. Infected cells were 
fractionated into nuclear and (a) cytoplasmic fractions and nucleic acids extracted, purified and divided into two aliquots. One 
aliquot was treated with RNAse A, re-purified and used for DNA quantification. The other aliquot was treated with RNAse-
free DNAse and used for first-strand cDNA synthesis. Cyclophillin A cDNA was then amplified by PCR in each fraction to 
examine cross-contamination of nuclear fractions with cytoplasmic material and the overall efficiency of first-strand cDNA syn-
thesis. Cyt, cytoplasmic fractions; Nu, nuclear fractions; W, wild-type virus; M, mutant virus; RT-, cytoplasmic fraction with no 
RT during first-strand cDNA synthesis; ctr-, primers only; Mw, GeneRuler 100 bp DNA molecular weigh marker. The band 
migrating at approximately 500 bp is cyclophilin A, lower molecular weigh bands are PCR artefacts. The experiments were per-
formed using 10 fold serial dilutions of the cDNA mix. (B) HIV-1 RNA accumulates in the nuclei shortly after infection. HeLa 
cells were infected at an MOI of approximately 0.2 with a VSV-G pseudotyped HIV-1 vector (wild type) or with the same 
amount (p24 normalized) of vector with a mutation in RT and unable to reverse transcribe (RT-). Cells were incubated for 2 
hours at 4°C and then 4 hours at 37°C following which samples were fractionated in nuclear and cytoplasmic fractions and 
treated as described in (A). Taqman PCR was used to measure the amount of viral DNA and RNA in each fraction. First-strand 
cDNA synthesis reactions carried out in the absence of RT gave undetectable signal. Values shown are average values ± SD of 
triplicate experiments. Similar results were obtained in two independent experiments. (C) Accumulation of HIV-1 DNA is 
reduced in imp7 KD cells. HeLa DxR or imp7 KD cells were infected with the same dose of a VSV-G pseudotyped HIV-1 vec-
tor, incubated 2 hours at 4°C and then 6 hours at 37°C, following which nuclear and cytoplasmic extracts were prepared and 
treated as described in (A). After first-strand cDNA synthesis, Taqman PCR was used to measure the amount of viral DNA 
and RNA in each fraction. First-strand cDNA synthesis reactions carried out in the absence of RT gave undetectable signal. Val-
ues shown are average copy number of viral RNA or DNA/μg total nucleic acids ± SD of triplicate experiments. Similar results 
were obtained in two independent experiments.Retrovirology 2009, 6:11 http://www.retrovirology.com/content/6/1/11
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Imp7 KD inhibits plasmid DNA transfection Figure 7
Imp7 KD inhibits plasmid DNA transfection. (A) HeLa DxR KD (shDxR), imp7 KD (shimp7) and imp7 back comple-
mented cells (shimp7+7R) were plated onto 6-well plates and transfected the next day with different amounts of the linearized 
HIV-1 plasmid DNA (pHR') complexed with FuGene 6. Twenty-four hours after transfection, the percentage of GFP+ cells was 
measured by flow cytometry. (B) HeLa DxR KD cells (DxR) and two different imp7 KD clones (please refer to Figure 2D) 
were plated onto 24-well plates and transfected as described in panel A. GFP+ cells were counted twenty four hours after 
transfection by flow cytometry. Note that 1/4 of the DNA was used in experiments shown in panel B compared to panel A 
because cells were plated onto 24-well plates. Bars represent the average value ± SD of three independent experiments. (C) 
HeLa DxR and imp7 KD cells were plated into 6 well plates with or without 1.5 micrograms/ml aphidicolin for 24 hours. Cells 
were then transfected with the indicated amount of linearized plasmid DNA (pHR') as described in (A) and analyzed by flow 
cytometry 24 hours later. Data are expressed as fold inhibition relative to shDxR cells and are representative of two independ-
ent experiments.Retrovirology 2009, 6:11 http://www.retrovirology.com/content/6/1/11
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imp7 KD clones (Figure 7B). Moreover, the inhibition of
DNA transfection was observed using the SIVmac vector
plasmid and a non-retroviral plasmid (not shown), indi-
cating that it was not DNA sequence-dependent.
Imp7 KD cells grew more slowly than DxR cells and this
might have influenced DNA transfection efficiency. To
rule out this possibility, imp7 KD and DxR cells were
arrested in the cell cycle by treatment with aphidicolin so
that conditions for both cell types were equal at the time
of transfection. Treated and untreated cells were trans-
fected with linearized plasmid DNA and analyzed for GFP
expression 24 hours later (Figure 7C). Cell cycle arrest
clearly reduced the efficiency of DNA transfection in all
cell types but the reduction was significantly more pro-
nounced in imp7 KD cells compared to DxR cells. Similar
results were obtained with circular plasmid DNA (not
shown). These data suggested that differences in the rate
of cell division could not account for the differences in
DNA transfection efficiency observed in DxR and imp7
KD cells.
Discussion
We have found that HIV-1 DNA associates with nuclei of
infected cells with remarkable efficiency and speed, that
imp7 influences the kinetics of HIV-1 DNA nuclear traf-
ficking, and that interaction of imp7 with IN is critical to
this end. Furthermore, our data suggest that lentiviruses
may have evolved different mechanisms for nuclear traf-
ficking of their RTCs.
Several lines of evidence support our conclusions. HIV-1
infection was impaired in stable imp7 KD cells only at ear-
lier time points and the effect was specific because back
complementation of imp7 rescued the phenotype. More-
over, the lower level of HIV-1 infection in imp7 KD cells
could not be simply explained by cell toxicity or other off-
site effects because SIVmac and HIV-2 were not affected.
The different behaviour of HIV-1 and HIV-2 or SIVmac in
imp7 KD cells was surprising and raised the possibility
that these viruses may use distinct pathways for nuclear
trafficking.
Imp7 has been shown to bind to HIV-1 IN [20,37] and
mutations that abolish this interaction were shown to
inhibit both reverse transcription and nuclear entry [37].
However, because of the pleiotropic effects that IN muta-
tions have on virus replication, it was not possible to
firmly conclude that the imp7-IN interaction was respon-
sible for the observed phenotype [37]. We found that HIV-
2 and SIVmac infection was not significantly impaired in
imp7 KD cells and this prompted us to test if their INs
were able to bind to imp7. Our pull down interaction
assays confirmed that imp7 does indeed specifically bind
HIV-1 IN. Side-by-side comparisons showed that the
interaction is significantly weaker with HIV-2 and SIVmac
INs, while EIAV IN did not show detectable binding.
Remarkably, the apparent binding affinity closely corre-
lated with the infectivity of the lentiviruses on imp7 KD
cells, strongly suggesting that the imp7-IN interaction is
critical for imp7 function. Overall the available evidence
points to the existence of varied and possibly redundant
pathways for nuclear import of lentiviruses.
To test if imp7 KD inhibited RTC nuclear transport, we
performed fractionation assays to separate nuclei from
cytoplasm following MLV and HIV-1 vector co-infection
and analysed viral DNA distribution by Taqman PCR.
These studies demonstrated that HIV-1 DNA associates
with the nuclei of infected cells with remarkable speed
and efficiency in both cycling and cell cycle-arrested cells.
Indeed, at 24 h post infection 90–95% of HIV-1 DNA was
found in the nuclear fraction. In contrast, nuclear accumu-
lation of MLV DNA was slower in cycling cells and was
further inhibited in cell cycle-arrested cells. Importantly,
imp7 KD appeared to inhibit nuclear accumulation of
HIV-1 DNA.
These results were confirmed in a subsequent set of exper-
iments in which HIV-1 infection and nuclear import (by
means of 2LTR detection) were followed over time. HIV-1
infection was reduced in imp7 KD cells compared to DxR
cells at 24 h post-infection and the difference was statisti-
cally significant. However the reduction was more modest
at later time points and was not statistically significant.
Viral DNA copy number gradually dropped in time in
both cell types, presumably due to dilution and degrada-
tion of un-integrated DNA forms. However, 2LTRs circular
viral DNA copy number was lower in imp7 KD cells com-
pared to DxR cells. Inhibition of infection was maximal at
24 h post-infection in imp7 KD cells but the difference in
2LTRs viral DNA levels between imp7 KD and control
cells was maximal at 48 h. It is possible that accumulation
of 2LTRs viral DNA takes longer than integration and viral
gene expression, which would explain the time lag. It is
also possible that accumulation of 2LTR DNA forms
requires a threshold of viral DNA in the nucleus. Together
the results of these two sets of experiments strongly sug-
gest that imp7 KD perturbs the kinetics of HIV-1 DNA traf-
ficking to the nucleus. These results reconcile apparently
discordant observations on the effect of imp7 KD in HIV-
1 infection. In one study where no difference was found
between imp7 KD and control cells, FACS analyses were
performed 96 h after HIV-1 infection [36], too late a time
point.
Our experimental approach, based on stable imp7 KD
cells, has certain limitations. Imp7 is one of the most
abundant nuclear import proteins, reaching a concentra-
tion of approximately 3 μM in HeLa cells [28]. Hence evenRetrovirology 2009, 6:11 http://www.retrovirology.com/content/6/1/11
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an effective and stable KD would presumably leave
enough imp7 to support essential cell functions. Residual
imp7 in the KD cells may at least in part explain the rela-
tively modest inhibition of HIV-1 infection. It should be
noted that a similarly modest inhibition of HIV-1 infec-
tion was also observed in HeLaP4 cells with a stable KD of
LEGDF/p75 [55], by now an established co-factor for
virus integration (reviewed in [46]). However, imp7 may
not be essential for HIV-1 infection and additional host
factors most likely participate in RTC nuclear import
[21,23,24].
We hypothesized [20] that imp7 could mediate nuclear
import of DNA by facilitating passage of the charged and
hydrophilic molecule through the central channel of the
nuclear pore complex, which appears to act as hydropho-
bic and size-selective phase [56-58]. A corollary to this
hypothesis is that reverse transcription of the viral
genome may be necessary for nuclear import. This was
tested using an HIV-1 mutant unable to reverse transcribe
[51,52]. This mutant virus buds normally and can effec-
tively saturate TRIM5αrh-mediated restriction, indicating
that it has no major post-entry defect [38]. A cell fraction-
ation procedure was devised to reduce contamination of
nuclei to minimal levels and to eliminate material associ-
ated with the external layer of the nuclear envelope. We
were also careful to isolate intact nuclei by sedimentation
in a sucrose cushion before extracting nucleic acids. A sig-
nificant amount of viral RNA was found in the nuclei
shortly after infection. Although we cannot exclude that
some viral RNA was still bound to the external nuclear
membrane, the fairly large quantity of viral RNA and the
undetectable levels of cyclophilin A mRNA in the nuclear
fraction suggested that the signal represented bona fide
nuclear import.
Our results are consistent with previous studies that
detected rapid nuclear accumulation of Visna virus, HIV-1
and avian sarcoma and leucosis viruses RNA genomes
[59-62]. Presently it is unclear if nuclear import of HIV-1
RNA has any physiological significance. Rapid trafficking
of viral RNA into the nucleus also suggests that HIV-1
uncoating may take place before completion of reverse
transcription.
Importantly, imp7 KD reduced nuclear accumulation of
viral DNA but not viral RNA. Consistent with the possibil-
ity that imp7 primarily facilitates translocation of DNA
across the nuclear pore complex, plasmid DNA transfec-
tion efficiency was also reduced in imp7 KD cells. The
defect was specific because it was reversed upon imp7
back-complementation and was sequence independent.
Cell cycle-arrest clearly inhibited DNA transfection but
imp7 KD had an additive effect. Taken together these
experiments suggested that HIV-1 might exploit imp7 to
maximise the nuclear import rate of its DNA genome.
Based on our results, we propose a model whereby
nuclear import factors need to be specifically recruited
onto the viral DNA within the HIV-1 RTC. Thus HIV-1 has
evolved the ability to recruit imp7 via IN. This promotes
trafficking of the viral DNA across the nuclear pore com-
plex by modifying the overall charge of the nucleoprotein
complex. Lentiviruses other than HIV-1 must have
evolved the ability to recruit alternative import factors
that have properties similar to imp7 and can also promote
DNA and/or RNA nuclear import. It will be interesting to
know which factor(s) substitute for imp7 in the other len-
tiviruses.
Why has HIV-1 evolved a very efficient and rapid nuclear
import mechanism and what could be the physiological
outcome of delaying this process? Our data showed that
imp7 KD reduced HIV-1 infection equally in cycling or
cell cycle-arrested cells. This suggests that normally HIV-1
does not enter the nucleus via two independent pathways,
one for cells in interphase and another for mitotic cells, in
agreement with previous studies [21,63-65]. Thus, HIV-1
may use the same mechanism to enter the nucleus of non-
dividing as well as dividing cells, such as activated CD4+
T-lymphocytes. Delayed nuclear import may be almost
inconsequential in long-lived cells, like terminally differ-
entiated macrophages, where the RTC would have suffi-
cient time to reach the nucleus before the infected cell
dies. In contrast, rapid import may be critical in short-
lived cells, such as activated CD4+ T-cells [66-68], where
a 24-h delay may make the difference between productive
and aborted infection. Because activated CD4+ T cells are
the main target for HIV-1 infection in vivo [66], we pro-
pose that, even if not essential for infection, host cell fac-
tors contributing to maximise the rate of HIV-1 infection
may play a role in AIDS pathogenesis.
Materials and methods
Cell culture and virus production
HeLa and 293 T cells were grown in Dulbecco's modified
Eagle's medium (DMEM) (Gibco Labs, Paisley, UK) sup-
plemented with 10% foetal calf serum (FCS) (Helena Bio-
science, Newcastle, UK) and 2 mM glutamine at 37°C in
5% CO2. Jurkat cells were grown in RPMI medium supple-
mented with 10% FCS at 37°C in 10% CO2. HIV-1 vectors
were made and purified as described previously [48] using
plasmids pHR' or pCSGW expressing GFP, pCMVΔR8.2,
(expressing gag-pol) or pHIVLAIDenv GFP and pMD.G,
expressing VSV-G [38,39,4]. MLV, SIVmac, HIV-2 and
EIAV vectors [40,42,69,70] were prepared and purified
using the same procedure. Reverse transcriptase (RT)
activity was measured by the Lenti-RT™ Activity Assay
(Cavidi Tech, Uppsala, Sweden) following the manufac-Retrovirology 2009, 6:11 http://www.retrovirology.com/content/6/1/11
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turer's instructions. HIV-1 p24 was quantified by ELISA
using the Coulter Antigen detection assay (Coulter Corp.,
Miami, FL).
Knock down of imp7
Synthetic oligonucleotides 5'-
ATGGAGCTCTGTATATGGTTGGTTCGCCAATCATAT-
GCAGGGCTCCATCTTTTT-3' and 5'-
CTAGAAAAAGATGGAGCCCTGCATATGATTGGCGAAC-
CAACCATATACAGAGCTCCAT-3' designed according to
siRNA sequences for imp7 (20) and oligonucleotides 5'-
TAATGCAGAAGAAGACCATGGGTTCGCCCATGGTCT-
TCTTCTGCATTACTTTTT-3' and 5'-
CTAGAAAAAGTAATGCAGAAGAAGACCATGGGCGAAC-
CCATGGTCTTCTTCTGCATTA-3' designed to target
DsRed were annealed and cloned into U6 promoter
driven HIV-1 vectors as previously described [38]. Infected
HeLa cells were selected in medium containing 1.5 micro-
grams/ml puromycin for 1 week; infected Jurkat cells were
selected in medium containing 12 micrograms/ml puro-
mycin for one week followed by selection in 6 micro-
grams/ml puromycin for a further week. After selection
cells were frozen in small aliquots in N2 or used within 4
passages. Two silent mutations were introduced into the
human importin 7 cDNA (Origene, Rockville, MD) using
the QuickChange II XL site directed mutagenesis kit (Strat-
agene, La Jolla, CA) with primer CCTCGAAAAAAAGAT-
GGTGCCCTGCACATGATTGGC (mutations in bold). The
plasmid was co-transfected with a Hygror pUC plasmid
into HeLa imp7 KD cells and cells selected in media con-
taining 500 micrograms/ml hygromycin B and 1 micro-
gram/ml puromycin. For infections, HeLa cells were
plated onto 24 well plates 4 × 104/well for sh-imp7 cells
and 3 × 104/well for sh-DxR cells. Cells were infected 24
hours later with 3-fold serial dilutions of viral stocks and
analyzed by FACS 24–72 hours after infection. Jurkat cells
were seeded into 96 well plates at 6 × 104/well (sh-imp7
cells) and 4 × 104/well (sh-DxR cells), infected with 3 fold
serial dilutions of viral stock and analysed by FACS 20 to
24 hours after infection.
PCR
PCR was performed in a final volume of 50 microliters
containing 1× PCR buffer, 100 μM each dNTP, 2.5 mM
MgCl2, 5 U Taq polymerase (Promega) and 30 picomoles
of each primer. Primer sequences were as follows: cyclo-
philin A (exon 1) forward 5'-ATCGAGAATTCCCACCAT-
GGTCAACCCCATCGTGTT-3' and cyclophilin A (exon 5)
reverse complementary 5'-TCGATTTCGAATTAGATTT-
GTCCACAGTCAGCAAT-3' Cycle parameter were: 94°C
for 3 min the first cycle, 94°C for 1 min, 550C for 1 min,
680C for 1 min for 27–35 cycles.
Cell cycle arrest
G1/S cell-cycle arrest was induced by addition of 1.5
micrograms/ml aphidicolin (Sigma, St. Louis, MO) for 24
h in standard medium. Cells were resuspended in 50
microliters PBS+3% FCS and fixed by addition of 1 ml
cold 80% ethanol and incubation at 4°C for 30 minutes.
Cells were resuspended in 0.5 ml PBS supplemented with
0.25% NP-40 (IGEPAL CA-630) (Sigma) and 2 U of
DNAse-free RNAse A (Roche), incubated for 30 mins at
37°C and centrifuged. The pellet was resuspended in 400
microliters PBS containing 0.2 micrograms/ml Propidium
iodide (Sigma) and analyzed by FACS. Cell viability was
analyzed with the LIVE/DEAD kit (Molecular Probes) fol-
lowing the manufacturers instructions.
Cell fractionation and detection of viral RNA and DNA
Approximately 5 × 106 HeLa cells were plated onto 175
cm2 flasks. The next day cells were infected at an MOI of
0.2, incubated 2 hours at 4°C and transferred at 37°C for
4–24 hours. Cells were trypsinized, washed once in PBSA
and the pellet was resuspended in 0.5 ml isotonic buffer 1
(20 mM HEPES pH 7.4, 110 mM KCl, 5 mM MgCl2, 0.5
mM EGTA, 1 mM DTT, 20 μg/ml aprotinin, 20 micro-
grams/ml leupeptin). Samples were centrifuged for 2 min
at 2,000 rpm at 4°C in a benchtop centrifuge; the pellet
was gently resuspended on ice in 50 microliters isotonic
buffer 1, then 0.5 ml isotonic buffer + 0.5% NP-40 was
added and samples were incubated for 5–7 mins on ice.
Following a 2 min centrifugation as before the superna-
tant was cleared by centrifugation at 9,000 rpm for 20 min
at 4°C. The pellet was washed in 0.5 ml isotonic buffer
once, resuspended in 1 ml isotonic buffer 2 (50 mM
TrisHCl pH 7.5, 25 mM KCl, 5 mM MgCl2, 0.25 M
sucrose) mixed with 2 ml isotonic buffer 2 + 2.3 M sucrose
and placed in a 5 ml ultracentrifuge tube on ice. Samples
were underlayed with 1 ml isotonic buffer 2 + 2.3 M
sucrose and centrifuged at 36,000 rpm in a Sorvall AH-
650 rotor at 4°C for 40 min. The interface containing
purified nuclei was collected and nuclei counted by mix-
ing with trypan blue. Nuclei and cytoplasmic extracts were
mixed with 1 volume of 2× lysis buffer (100 mM Tris-HCl
pH 8, 1% SDS, 10 mM EDTA, 50 micrograms/ml protein-
ase K), incubated for 4 hours at 55°C and nucleic acids
were isolated by phenol/cholorform and ethanol precipi-
tation. Samples were divided into aliquots; one aliquot
was treated with RNAse A for 1 hour at 37°C and then
subjected to phenol/chloroform extraction and ethanol
precipitation. Another aliquot was treated with 2 U/
micrograms nucleic acids ReQ1 DNAse in 1× buffer
(Promega) for 30 mins at 37°C, then supplemented with
2 mM EGTA to stop the reaction, and samples were incu-
bated at 60°C for 20 min. The Superscript III kit (Invitro-
gen) was used for first-strand cDNA synthesis primed by
random hexamers following the manufacturer's instruc-
tions. Control samples were incubated in parallel without
RT. TaqMan quantitative PCR was performed using an ABI
Prism 7000 thermocycler as described [48]. For amplifica-
tion of intermediate and late products of reverse transcrip-
tion, 0.3 μM of each GFP or HIV late primers [48], 0.15Retrovirology 2009, 6:11 http://www.retrovirology.com/content/6/1/11
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μM of the probe, 12.5 μl of Quantitect Probe Master Mix
(Qiagen) were used in a final volume of 25 μl. The stand-
ards were prepared with CNCG or pHR' plasmids in 10-
fold dilutions from 107 to 102 copies/microliter. 200–500
ng of template DNA was added per reaction. For amplifi-
cation of 2LTR circular DNA, the same conditions were
used with primers 2LTRqPCRF: 5'-AACTAGAGATCCCT-
CAGACCCTTTT-3' and 2LTRqPCRRC: 5'-CTTGTCT-
TCGTTGGGAGTGAATT-3' and probe 5'-FAM-
CTAGAGTTTTCCACACTGAC-0-TAMRA-3'. Standards
were prepared by PCR amplification of DNA from acutely
infected cells with primers 2LTRF 5'-GCCT-
CAATAAAGCTTGCCTGG-3' and 2LTRRC 5'-TCCCAG-
GCTCAGATCTGGTCTAAC-3'. The amplification product
was cloned into TOPO vector, amplified and confirmed
by sequencing. MLV DNA was amplified using primers
MLF-F, 5'-CATGGACACCCAGACCAG-3'; MLV RC 5'-
CGGATGGAGGAAGAGGAG-3'; MLV probe, 5'-FAM-
CCCCTACATCGTGACCTGGGAAGCC-TAMRA-3' and
pCNCG as standard.
Western blot
Antibody C-20 against Ran was purchased from Santa
Cruz Biotechnology (Santa Cruz, CA). The anti-imp 7
antibody was described previously [20]. Anti-rabbit and
anti-goat IgG HRP-conjugated antibodies were purchased
from Jackson Laboratories (Bar Harbor, MN) or Sigma-
Aldrich. After SDS PAGE, the proteins were transferred to
PVDF membranes (Bio-Rad, Hercules, CA) and probed
with the primary antibodies. HRP-conjugated secondary
antibodies were used diluted 1:3,000 in PBS containing
10% non-fat milk. Chemiluminescence (ECL, Amersham)
was used to develop the blots as described by the manu-
facturer. Autoradiography films were exposed for different
periods of time to ensure linearity of the signal.
Transfections
HeLa cells were plated into 24-well plates at 4 × 104 cells/
well or in 6-well plates at 3 × 105 cells/well and transfected
the next day. To transfect cells in 24-well plates, 10 micro-
liters linearized plasmid (70 ng/μl in TE) were mixed with
a solution of 50 μl Opti-Mem medium (Invitrogen) and
4.6 μl Fugene-6 (Roche Molecular Biochemicals), incu-
bated for 15 mins at room temperature and then 0.5, 1, 3,
9 and 18 μl/well of the solution were added to the cells
after media change to 0.5 μl fresh DMEM + 10% FCS. To
transfect cells in 6-well plates all doses were scaled up by
a factor of four. Cells were analyzed by FACS 24 hours
after transfection to detect GFP expression.
Recombinant proteins and pull-down experiments
To make pGEX6P-imp7, used for expression GST-tagged
Imp7, a BamHI/HindIII fragment of pQE9-imp7 [29],
spanning the imp7 coding region, was subcloned between
BamHI and SmaI sites of pGEX6P3 (GE Healthcare) (the
HindIII DNA end was filled in using T4 DNA polymerase
to allow blunt-end ligation). Escherichia coli Rosetta 2
cells (Novagen) transformed with pGEX6P-imp7 were
grown in shake flasks in Lennox LB medium at 30°C to an
A600 of 0.9–1.0 before addition of 1% glycerol, 2.5% eth-
anol, and 0.25 mM IPTG. Following 5-h induction at
15°C, the cells were harvested and stored at -80°C. To iso-
late GST-imp7, thawed bacterial paste was lysed by soni-
cation in core buffer (250 mM NaCl, 10% (v/v) glycerol,
50 mM Tris-HCl, pH 7.4), supplemented with 10 mM
DTT, 2 mM EDTA, and 0.5 mM PMSF. Cell debris were
removed by centrifugation, and GST-imp7 was captured
on glutathione sepharose (GE Healthcare). The protein
was eluted in core buffer supplemented with 50 mM
reduced glutathione or incubated with human rhinovirus
14 3C protease to release untagged imp7. The proteins
were further purified by size exclusion chromatography
on a preparative Superdex 200 column (GE Healthcare)
operated in 250 mM NaCl, 50 mM Tris-HCl, pH 7.4, con-
centrated using a Centriprep-YM3 device (Millipore), sup-
plemented with 10 mM DTT and 10% glycerol and snap-
frozen in liquid nitrogen. C-terminally His6-tagged and
non-tagged IN proteins were prepared as previously
described [43,71,72].
Pull down assays were done according to published proce-
dures [43,73,74] with slight modifications. For GST pull-
downs, 10 micrograms BSA and 10 micrograms untagged
IN protein were added to ice-cold suspension of 15 μl glu-
tathione sepharose (settled resin volume) carrying immo-
bilized GST or a GST fusion protein (2 mg/ml) in 800 μl
pull down buffer 1 (PDB1: 130 mM NaCl, 2 mM MgCl2, 2
mM DTT, 0.1% NP-40, 50 mM Bis-Tris propane-HCl, pH
7.45). The samples were gently rocked for 2.5 h at 4°C and
washed in three changes of ice-cold PDB1, allowing the
beads to precipitate on ice after each wash. The proteins
eluted by boiling in Laemmli SDS sample buffer were
resolved in tris-glycine 11% SDS PAGE gels. Concentration
of NaCl in PDB1 was adjusted as explained in the results
section. For His6-tag pull down assays, 10 ug of each BSA,
Imp-7, and a C-terminally His6-tagged IN protein were
incubated with 20 ul Ni-NTA agarose (Qiagen) suspended
in 800 ul of pull down buffer 2 (PDB2: 150 mM NaCl, 2
mM MgCl2, 35 mM imidazole, 0.1% NP-40, 50 mM Bis-
Tris propane-HCl, pH 7.45) for 5 h at 4°C with gentle rock-
ing. The beads washed in three changes of ice cold PDB2
were boiled in Laemmli SDS sample buffer supplemented
with 50 mM EDTA, and the eluted proteins were resolved
in tricine 10–20% SDS PAGE gels (Invitrogen).
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